At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Tesofensine/Metoprolol +1 moredrug
Likely dose
Tesofensine/Metoprolol 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Two-center, Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (T2DM)
In Brief
A Phase 2 clinical trial evaluating Tesofensine/Metoprolol and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 60 participants across 1 site.
Detailed Summary
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesGermany
CollaboratorsProfil Institut für Stoffwechselforschung GmbH
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionJan 2017
Study CompletionMar 2017
TodayJul 2026
First PostedApr 14, 2016
Enrollment StartApr 1, 2016
Primary CompletionJan 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.2 years ago
Interventions
Tesofensine/Metoprololdrug
Tesofensine 0.5 mg + Metoprolol 100 mg
Placebodrug